Malaghan Institute of Medical Research: securing medical discovery in New Zealand

Malaghan researchers are creating a portfolio of promising therapies, including Avalia Immunotherapies, which are designed to support the treatment of cancer and other diseases. Photo: Malaghan Institute.

A major challenge for New Zealand-made biomedical discoveries is making the pivotal leap from laboratory to the market, where they become available to the benefit of the wider community.

By opening up a new discovery area in chemical-immunology the Malaghan Institute and the Ferrier Institute are using their combined skills to build innovative new molecules for use in therapy. With the Malaghan’s HRC IRO-funded research into the workings of the human immune system, medical scientists at Malaghan are able to create a portfolio of promising therapies for a range of different diseases.

The most notable is Avalia Immunotherapies which has taken promising new chemical entities through preclinical studies and is working through the rigorous commercialisation phase here in New Zealand. The ultimate purpose of creating commercial entities is to give Kiwis early access to this ground-breaking technology and provide a sturdy platform for the country’s nascent pharmaceutical industry.

For more about the research underway at the Malaghan Institute of Medical Research please see:

Date posted: 19 March 2018

Facebook Feed